Ushbu ish iqtibos qilgan ishlar
298 ta ish
Ish: Pyroptosis-inducing nanomedicines: A dual-mode therapeutic framework for apoptosis-resistant lung cancer
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Edward B. Garon, Naiyer A. Rizvi, Rina Hui +24
Maqola20153 iqtibosABIEnhancement of Antitumor Immunity by CTLA-4 Blockade
Dana R. Leach, Matthew F. Krummel, James P. Allison
Maqola19963 iqtibosABIRole of pyroptosis in inflammation and cancer
Wei Xiang, Feng Xie, Xiaoxue Zhou +7
Sharh maqolaOchiq kirish20222 iqtibosABIImmunotherapy of targeting MDSCs in tumor microenvironment
Hongshu Sui, Shengyi Dongye, Xiaocui Liu +11
Sharh maqolaOchiq kirish20222 iqtibosABIClonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade
Nicholas McGranahan, Andrew J.S. Furness, Rachel Rosenthal +33
MaqolaOchiq kirish20162 iqtibosABIAdvancements in Liposomal Nanomedicines: Innovative Formulations, Therapeutic Applications, and Future Directions in Precision Medicine
Zahra Izadiyan, Misni Misran, Katayoon Kalantari +5
Sharh maqolaOchiq kirish20252 iqtibosABIMetal–organic framework-based smart stimuli-responsive drug delivery systems for cancer therapy: advances, challenges, and future perspectives
Ziliang Guo, Yuzhen Xiao, Wenting Wu +5
Sharh maqolaOchiq kirish20252 iqtibosABICancer immunoediting: from immunosurveillance to tumor escape
Gavin P. Dunn, Allen T. Bruce, Hiroaki Ikeda +2
Sharh maqola20022 iqtibosABIAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo +17
Maqola20182 iqtibosABIThe immune contexture in cancer prognosis and treatment
Wolf H. Fridman, Laurence Zitvogel, Catherine Sautès‐Fridman +1
Sharh maqola20172 iqtibosABIMitochondria as multifaceted regulators of cell death
Florian J. Bock, Stephen W. G. Tait
Sharh maqola20192 iqtibosABINivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer
Matthew D. Hellmann, Luis Paz‐Ares, Reyes Bernabe Caro +23
Maqola20192 iqtibosABI